Tazverik (tazemetostat) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has relapsed or refractory disease
• Patient has tried at least two prior systemic therapies OR according to the prescriber there are no appropriate alternative therapies

Reauthorization criteria

• Patient continues to meet initial criteria

Approval duration

1 year